Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Ophthalmol ; 5(4): 430-3, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22937500

RESUMEN

AIM: To observe the changes of basic fibroblast growth factor (bFGF) content in anterior chamber before and after extra capsular lens extraction for investigating the mechanism of low molecular weight heparin (LMWH) inhibiting anterior chamber inflammation. METHODS: Eighty-four rabbits were randomly divided into control and experimental group, 42 rabbits in each group. Extra capsular lens extraction was done on unilateral eye in each rabbit. LMWH was perfused into anterior chamber by the concentration of 50U/mL at the end of operation in experimental group. The degrees of corneal edema, aqueous flare and fibrin were evaluated with slit lamp microscope on postoperative day 1, 3, 6, 15, 30, 45 and 60, respectively. Six eyes of each group were at each time point. Contents of bFGF in aqueous humor were determined by ELISA after animals were killed. Another six eyes were used for determining the base line level of bFGF in aqueous humor. RESULTS: The degrees of corneal edema, aqueous flare and fibrin in experimental group were significantly lighter than those in control group (P<0.01) on postoperative day 1, 3 and 6, respectively. No difference was showed between the two groups at other point time. Contents of bFGF in aqueous humor increased at the same time. bFGF content reached peak on postoperative day 1 in experimental group, while on postoperative day 6 in control group. Contents of bFGF in the two groups declined slowly after reaching peak. The bFGF content in control group were significantly higher than that in experimental group 1-30 days after surgery (P<0.05). No significant differences were shown between the two groups on postoperative day 45 and 60, respectively. CONCLUSION: Perfusion with LMWH by the concentration of 50U/mL can significantly reduce anterior chamber inflammation after extra capsular lens extraction in rabbits, which may be related to down regulation of bFGF content in aqueous humor.

2.
Zhonghua Yan Ke Za Zhi ; 46(6): 525-31, 2010 Jun.
Artículo en Chino | MEDLINE | ID: mdl-21055198

RESUMEN

OBJECTIVE: To evaluate the different efficacy and safety to the treatment of bacterial conjunctivitis between the fluoroquinolone antibiotics gatifloxacin and levofloxacin. METHODS: A multi-centre, random, double-blind and control trial was performed in six centers including Eye Ear Nose and Throat Hospital of Fudan University, Henan Eye Institute, Eye Hospital Affiliated to Wenzhou Medical College, the First Affiliated Hospital Of Nanjing Medical University, Xijing Hospital Affiliated to the Fourth Military Medical University, the Second Affiliated Hospital of Xi'an Jiaotong University between August 2006 and October 2007. The levofloxacin was set as the efficient control. Two hundred and thirty-five patients (235 eyes) that diagnosed as bacterial conjunctivitis were randomly divided into two groups by the method of randomized blocks, the test group (gatifloxacin) had 118 eyes and the control (levofloxacin) group had 117 eyes. The drug delivery into conjunctival sac was performed at a 7-day period (two drops per time, eight times per day at the first two days and two drops per time, four times per day at the following 5 days). All participants were given the conjunctival sac germ culture and drug sensitive test before and after the study. The combination score of signs and symptoms and evaluation of safety were conducted at the pre-delivery day, the (4 ± 1) and (7 ± 1) delivery day. The statistic analysis was conducted by CMH χ(2) test, Pearson χ(2) test and Fisher's exact probabilities test. RESULTS: The efficacy of the two groups was 94.0% (110/117 eyes) in gatifloxacin group and 93.8% (106/113 eyes) in levofloxacin group with no significant difference (χ(2) = 0.052, P = 0.8201). There was also no difference in the bacteria clearance between the two groups [gatifloxacin versus levofloxacin, 94.1% (80/85 eyes) versus 92.5% (74/80 eyes), P = 0.3470]. The decrease of combination score of signs and symptoms at the (4 ± 1) delivery day was 4.436 ± 2.310 in the gatifloxacin group and 3.814 ± 1.962 in the levofloxacin group, the difference of which was significant (F = 7.280, P = 0.0075). This trend was also proved at the (7 ± 1) delivery day (gatifloxacin versus levofloxacin, 7.487 ± 2.821 versus 6.912 ± 2.911, F = 4.060, P = 0.0452). The visual acuity and the tolerance after local application of the eye drops between the two groups had no difference (the visual acuity F = 1.04, P = 0.3080; the tolerance after local admission χ(2) = 0.1372, P = 0.7111). According to the result of the germ culture, the major pathogenic bacteria were Gram-positive bacteria (totally 20 kinds of Gram-positive bacteria and 8 kinds of Gram-negative bacteria). The MIC and drug resistance of gatifloxacin to the Gram-positive bacteria was lower than that of the levofloxacin (Staphylococcus Epidermidis, Staphylococcus Aureus, coagulase negative Staphylococcus, α-hemolytic Streptococcus). CONCLUSIONS: The gatifloxacin eye drop has a good therapeutic effect to the bacterial conjunctivitis. It can effectively clear the pathogen with fast and strong effect. Moreover, it has a low MIC in vitro, advance a prospect in drug resistance, safety and ocular tolerance.


Asunto(s)
Conjuntivitis Bacteriana/tratamiento farmacológico , Fluoroquinolonas/uso terapéutico , Levofloxacino , Ofloxacino/uso terapéutico , Adolescente , Adulto , Método Doble Ciego , Femenino , Gatifloxacina , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven
3.
Curr Eye Res ; 34(4): 287-96, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19373577

RESUMEN

PURPOSE: The purpose of this study is to assess the change of uveoscleral outflow induced by moxonidine and to investigate whether the increase of uveoscleral outflow induced by moxonidine is mediated by alpha1, alpha2, or I1 receptors. METHODS: 0.05% moxonidine was topically and unilaterally administered in rabbit eyes with or without pretreatment of prazosin, yohimbine, efaroxan, or AGN 192403, as indicated. We injected fluorescein isothiocyanate-bovine serum albumin (FITC-BSA) into the anterior chamber and observed the fluorescence intensity of the uveoscleral outflow. Finally, the volume of uveoscleral outflow was calculated based on the fluorescence intensities captured. RESULTS: A bilateral increase of fluorescence intensity was observed along the uveoscleral outflow pathway following moxonidine administration, especially in the ciliary body and supraciliochoroidal space. Pretreatment with prazosin further enhanced the bilateral increase of fluorescence intensity at between 2 and 4 hours after moxonidine administration. The response of moxonidine was antagonized by either yohimbine, an alpha2 receptor antagonist, or efaroxan, an I1/alpha2 receptor antagonist. The antagonizing effect of yohimbine was more potent than that of efaroxan. The moxonidne-induced response was not antagonized by AGN 192403, an I1 receptor antagonist. The bilateral volumes of aqueous humor within the uveoscleral pathway increased significantly induced by moxonidine (p < 0.01 versus control). The increased bilateral volumes of uveoscleral outflow were 0.381 +/- 0.073 and 0.376 +/- 0.095 mu l/min, respectively. CONCLUSION: These results suggest that topical, unilateral administration of moxonidine causes a bilateral increase of aqueous humor via the uveoscleral outflow pathway. The moxonidine-induced increase of uveoscleral outflow is mediated by alpha2 adrenergic receptors, not by I1 imidazoline receptors.


Asunto(s)
Humor Acuoso/metabolismo , Imidazoles/farmacología , Receptores de Imidazolina/metabolismo , Receptores Adrenérgicos alfa 2/metabolismo , Esclerótica/metabolismo , Úvea/metabolismo , Administración Tópica , Antagonistas Adrenérgicos alfa/farmacología , Animales , Humor Acuoso/efectos de los fármacos , Benzofuranos/farmacología , Compuestos Bicíclicos con Puentes/farmacología , Sinergismo Farmacológico , Fluoresceína-5-Isotiocianato/análogos & derivados , Heptanos/farmacología , Imidazoles/administración & dosificación , Receptores de Imidazolina/antagonistas & inhibidores , Prazosina/farmacología , Conejos , Esclerótica/efectos de los fármacos , Albúmina Sérica Bovina , Úvea/efectos de los fármacos , Yohimbina/farmacología
4.
Yan Ke Xue Bao ; 24(1): 44-7, 2008 Mar.
Artículo en Chino | MEDLINE | ID: mdl-18709957

RESUMEN

AIM: To analyze the clinical characteristics, incidence and risk of retinal detachment (RD) after cataract surgery and posterior chamber intraocular lens implantation in high myopic patients. METHODS: The medical records of 146 high myopic patients (232 eyes) who underwent cataract surgery and posterior chamber intraocular lens implantation were studied retrospectively. The development of RD was followed up over a 3-year period, and its characteristics were determined. All of the eyes received a comprehensive ophthalmological examination, including best-corrected visual acuity measurements, a dilated fundus examination and axial length measured by A-scan ultrasonography. RESULTS: RD developed in 15 eyes of 15 patients. All the 15 eyes needed vitreo-retinal surgery. The mean interval between cataract surgery and the development of RD was 10 +/- 9 months (range 0.5-32 months). The visual results of the eyes after anatomical successful vitreo-retinal surgery ranged from finger count/10 cm to 0.06. 80% (12/15) of the eyes had a worse vision after the surgery than that before cataract surgery. Posterior capsular tear were associated significantly with RD (P < 0.01). Approximately 60% (9/15) of retinal detachment was attributable to posterior capsule tear during cataract surgery. CONCLUSION: Incidence of RD in high myopic patients after cataract surgery was 6.4%. RD was the potentially serious complication and tended to develop more frequently in eyes with posterior capsular rupture during cataract surgery. It is crucial to examine retinal status after cataract surgery and to have a close follow-up to prevent retinal complications, especially for patients with posterior capsular disruption.


Asunto(s)
Extracción de Catarata/efectos adversos , Implantación de Lentes Intraoculares/efectos adversos , Desprendimiento de Retina/etiología , Anciano , Anciano de 80 o más Años , Catarata/terapia , Femenino , Humanos , Masculino , Persona de Mediana Edad , Miopía/cirugía , Complicaciones Posoperatorias , Estudios Retrospectivos
5.
Yan Ke Xue Bao ; 21(3): 142-6, 2005 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17162851

RESUMEN

PURPOSE: To determine whether triamcinolone acetonide (TA ) staining facilitates posterior hyaloid removal in patients undergoing pars plana vitrectomy (PPV) for retinal disease. METHODS: A triamcinolone acetonide(TA)-assisted vitrectomy was performed on patients with the following disease: proliferative diabetic retinopathy (5 eyes), central retinal vein occlusion (5 eyes), macuar hole (3 eyes), and epiretinal membrane (2 eyes). Eyes without apparent preoperative posterior vitreous detachment were enrolled in this study. After a core PPV, TA aqueous suspension (40 mg/ml) was injected into the mid vitreous cavity to visualize the posterior hyaloid, thus allowing a complete posterior hyaloid separation and removal. The visual acuity, intraocular pressure (IOP), tamponade, corneal pathology, after-cataract, vitreous hemorrhage, and necessity for reoperation were thereafter examined for at least 3 months after surgery. RESULTS: In all patients, the vitreous body was clearly seen by means of triamcinolone during surgery, and complete removal of posterior hyaloid was facilitated and confirmed. Retina was attached in 14 of 15 eyes, and vision acuity was improved in 9 of 15 eyes. Two eyes showed transient postoperative IOP elevation, 2 eyes had after cataract formation and l eye had cataract progression. Vitreous hemorrhage occurred in 1 eye. No eye had corneal pathology. CONCLUSION: Triamcinolone improved the visibility of the hyaloid and the safety of surgical procedures during PPV. No obvious adverse effect due to toxicity of TA accrued in TA-assisted PPV.


Asunto(s)
Retinopatía Diabética/cirugía , Membrana Epirretinal/cirugía , Glucocorticoides/administración & dosificación , Mácula Lútea/cirugía , Oclusión de la Vena Retiniana/cirugía , Triamcinolona Acetonida/administración & dosificación , Vitrectomía/métodos , Desprendimiento del Vítreo/cirugía , Humanos , Mácula Lútea/patología , Resultado del Tratamiento , Agudeza Visual
6.
Zhonghua Yan Ke Za Zhi ; 41(12): 1112-8, 2005 Dec.
Artículo en Chino | MEDLINE | ID: mdl-16409766

RESUMEN

OBJECTIVE: To determine the effect of Y27632, a specific inhibitor of p160 Rho-associated coiled-coil forming protein kinase (ROCK), on experimental rabbit PVR. METHODS: Cultured rabbit retinal pigment epithelial cells were used in the experiments. The effects of Y27632 on RPE alpha-SMA (smooth muscle actin) stress fiber formation were studied by immuno-fluorescent staining. An in vitro type I collagen gel contraction assay and MTT assay were used to detect the effect of Y27632 on RPE cell contractile force and proliferation. Cultured 6 th passage rabbit RPE cells were injected intravitreally to induce the PVR model and then followed injection of 50 micromol/L of Y27632. The presence of tractional retinal detachment (TRD) was assessed to evaluate the effect of this agent in vivo. Electroretinography and histological studies were performed after intravitreal injection of Y27632 into untreated eyes to evaluate toxicity. RESULTS: The results showed that Y27632 disrupted SMA stress fiber formation in the cultured RPE cells and impaired contractile force generated by RPE cells (t = 16.212, P < 0.01). Development of TRD was significantly reduced (P < 0.01) with 50 micromol/L of Y27632. No obvious histological or retinal functional damage was found in the Y27632-treated group. CONCLUSION: p160 ROCK specific inhibitor Y27632 decreased contractile force generated by RPE cells and attenuated PVR without significant side effect in rabbit. This reagent could be potential therapeutically method in the treatment of PVR.


Asunto(s)
Amidas/farmacología , Inhibidores Enzimáticos/farmacología , Epitelio Pigmentado Ocular/efectos de los fármacos , Piridinas/farmacología , Vitreorretinopatía Proliferativa/prevención & control , Quinasas Asociadas a rho/antagonistas & inhibidores , Animales , Células Cultivadas , Femenino , Masculino , Miocitos del Músculo Liso/citología , Miocitos del Músculo Liso/efectos de los fármacos , Miocitos del Músculo Liso/enzimología , Epitelio Pigmentado Ocular/citología , Epitelio Pigmentado Ocular/enzimología , Conejos , Retina/efectos de los fármacos , Vitreorretinopatía Proliferativa/enzimología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA